We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
22 April 2019
On 8 March 2019 Justice Fothergill granted Valeant Canada's application for an order prohibiting the minister of health from issuing a notice of compliance to Generic Partners for its generic version of Valeant's Glumetza, a metformin formulation.(1)
Generic Partners had alleged that Patent 2,290,624, for controlled release dosage forms of drugs such as metformin, was invalid for:
The patent claimed swellable dosage forms that included:
When these elements are combined, they increase gastric retention of the dosage form.
With respect to anticipation and double patenting, the court found that the prior art document on which Generic Partners had relied for both allegations did not disclose all three of the size, shape and time elements of the claimed formulations. With respect to obviousness, the court found that although the size and time elements may have been disclosed, neither the shape element nor the combination of all three elements had been. Given that it was unknown whether dosage shapes would affect gastric retention, it could not be obvious to use an oval shape. With respect to insufficiency, the court accepted Valeant's evidence that any experimentation required to optimise the claimed dosage forms would be routine and found the lack of data and examples in the patent irrelevant to sufficiency.
Generic Partners may appeal.
For further information on this topic please contact Abigail Smith at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar website can be accessed at www.smart-biggar.ca.
(1) Valeant Canada v Generic Partners Canada (2019 FC 253).
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.